Inmune Bio (INMB) Stock
Small biotech developing immune system therapies in trials. Here's the price, business snapshot, and what's worth knowing about Inmune Bio in August 2026.
INMUNE BIO INC (INMB) is a small‑cap, clinical‑stage biotechnology company focused on developing therapies that modulate innate immunity. With a market capitalisation of roughly $50 million, the company is likely pre‑revenue and dependent on clinical progress, partnerships and financing to advance its programmes. Key considerations for investors include high scientific and execution risk: clinical trial outcomes and regulatory decisions tend to be primary share‑price drivers, and positive data can materially affect valuation while setbacks may be swift. Cash runway and any licensing or collaboration agreements are important to monitor, as small biotechs frequently need further capital which can dilute existing holders. Liquidity may be limited and price moves can be volatile. This summary is for educational purposes only and not personalised financial advice; investors should assess the science, management, trial design and how a speculative biotech fits into a diversified, risk‑managed portfolio.
About This Stock
INMUNE BIO INC
INMB
Current Price
$2.24
Potential 12 Month Profit
834.34%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
INMB
Market Cap
$61.89M
Potential 12 Month Profit
834.34%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying INMUNE BIO's stock with a target price of $21.5, indicating significant growth potential.
Financial Health
Inmune Bio Inc has very low revenue and modest cash flow, indicating financial difficulties.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Why You’ll Want to Watch This Stock
Clinical‑stage focus
Progress depends on trial data and regulatory signals; positive results can change valuation quickly, though outcomes remain uncertain.
Catalysts to watch
Trial readouts, partnership announcements and financing updates can move the share price — monitor official filings and company releases.
Risk and liquidity
Small market cap often means higher volatility and limited liquidity; consider diversification and that this is educational, not personal advice.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.